StockData
Mesoblast Ltd logo

Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30
$11.91−0.54 (-4.34%)

Close on Nov 17, 2026Market cap $1.54BP/E –Yield –

Mesoblast operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Mesoblast's operating cash flow for the twelve months ending Jun 30, 2023 was -$63.27M. For fiscal 2026 it was -$43.83M. The highest annual figure on record is -$43.83M in fiscal 2026.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$43.83M–
FY2025Jun 30, 2025-$49.95M–
FY2024Jun 30, 2024-$48.46M–
FY2023Jun 30, 2023-$63.27M–
FY2022Jun 30, 2022-$65.78M–
FY2021Jun 30, 2021-$100.75M–
FY2020Jun 30, 2020-$50.42M–
FY2019Jun 30, 2019-$57.79M–
FY2018Jun 30, 2018-$75.01M–
FY2017Jun 30, 2017-$95.47M–
FY2016Jun 30, 2016-$88.00M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2023CQ2 2023Jun 30, 2023-$16.28M–
Q3 FY2023CQ1 2023Mar 31, 2023-$16.25M–
Q2 FY2023CQ4 2022Dec 31, 2022-$16.45M–
Q1 FY2023CQ3 2022Sep 30, 2022-$14.29M–
Q4 FY2022CQ2 2022Jun 30, 2022-$13.89M–
Q3 FY2022CQ1 2022Mar 31, 2022-$15.47M–
Q2 FY2022CQ4 2021Dec 31, 2021-$18.22M–
Q1 FY2022CQ3 2021Sep 30, 2021-$18.20M–
Q4 FY2021CQ2 2021Jun 30, 2021-$18.92M–
Q3 FY2021CQ1 2021Mar 31, 2021-$24.47M–
Q2 FY2021CQ4 2020Dec 31, 2020-$29.19M–
Q1 FY2021CQ3 2020Sep 30, 2020-$28.17M–
Q4 FY2020CQ2 2020Jun 30, 2020-$13.64M–
Q3 FY2020CQ1 2020Mar 31, 2020-$19.90M–
Q2 FY2020CQ4 2019Dec 31, 2019-$1.33M-165.5%
Q1 FY2020CQ3 2019Sep 30, 2019-$15.56M–
Q4 FY2019CQ2 2019Jun 30, 2019-$19.09M–
Q3 FY2019CQ1 2019Mar 31, 2019-$21.19M–
Q2 FY2019CQ4 2018Dec 31, 2018$2.03M–
Q1 FY2019CQ3 2018Sep 30, 2018-$19.54M–
Q4 FY2018CQ2 2018Jun 30, 2018-$20.19M–
Q3 FY2018CQ1 2018Mar 31, 2018-$19.60M–

More Mesoblast figures

See a number that looks wrong?